Signaling Events During Induction of Plasminogen Activator Inhibitor-1 Expression by Sphingosylphosphorylcholine in Cultured Human Dermal Fibroblasts  by Kye, Kyung-Chae et al.
Signaling Events During Induction of Plasminogen Activator
Inhibitor-1 Expression by Sphingosylphosphorylcholine in
Cultured Human Dermal Fibroblasts
Kyung-Chae Kye, Eun-Kyung Chae, Yong-Jun Piao, Seonyang Park,w Jang-Kyu Park, Chang Deok
Kim, Jeung-Hoon Lee, and Ki-Beom Suhr
Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea; wDepartment of Internal Medicine, College of Medicine,
Seoul National University Hospital, Seoul, Korea
Sphingosylphosphorylcholine (SPC) is a bioactive sphingolipid metabolite that can enhance wound healing. In a
search for effectors downstream of SPC in the wound-healing process, we found that the expression of the gene for
plasminogen activator inhibitor-1 (PAI-1) was signiﬁcantly affected. ELISA and western blot analyses showed that
SPC markedly induced PAI-1 production in human dermal ﬁbroblasts cultured in vitro. Inhibition by pre-treatment
with pertussis toxin (PTx), but not by tyrphostin A47 (a receptor tyrosine kinase inhibitor), indicated that PTx-
sensitive G proteins were involved in SPC-induced PAI-1 expression. SPC elicited a rapid and transient increase
in intracellular calcium levels ([Ca2þ ]i), measured using laser scanning confocal microscopy, which was partly
mediated through PTx-sensitive G proteins. Pre-treatment with thapsigargin, but not with EGTA, abolished SPC-
induced PAI-1 expression, indicating the importance of Ca2þ release from internal stores. Phorbol-12-myristate-13-
acetate (PMA) induced the expression of PAI-1, and pre-treatment with Ro 31-8220 (a PKC inhibitor) markedly
suppressed SPC-induced PAI-1 expression. SPC-induced PAI-1 expression was also signiﬁcantly suppressed by
PD98059 (a speciﬁc MAPK kinase 1/2 inhibitor). Consistent with this result, SPC stimulated the phosphorylation
of p42/44 extracellular signal-regulated kinase (ERK). Together, these results suggest that SPC induces PAI-1
production through a G protein-coupled calcium increase and downstream kinase signaling events in cultured
human dermal ﬁbroblasts.
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Sphingolipid metabolites, such as sphingosine, sphin-
gosine-1-phosphate (S1P), sphingosylphosphorylcholine
(SPC), and lysophosphatidic acid (LPA), are important
signaling molecules in intracellular and/or extracellular
communications (Liscovitch and Cantley, 1994). SPC has
been shown to accelerate cutaneous wound healing, and
effect believed to be mainly due to its mitogenic potential
for many target cells, including keratinocytes, fibroblasts,
and endothelial cells (Sun et al, 1996; Wakita et al, 1998). In
addition, several lines of evidence suggest that SPC has
other important functions in the wound-healing process;
examples include the stimulation of endothelial cell migra-
tion and morphogenesis, the enhancement of fibroblast
contraction, and the induction of extracellular matrix (ECM)
component (Boguslawski et al, 2000; Suhr et al, 2000,
2003). Despite accumulating evidence for various functional
roles, the precise mechanism underlying the stimulation of
wound healing by SPC remains to be elucidated. In an effort
to find downstream effectors of SPC, we have performed
intensive in vivo and in vitro screening tests. We found that
the expression of plasminogen activator inhibitor-1 (PAI-1)
was greatly influenced by SPC treatment.
PAI-1, a member of the serine protease inhibitor (serpin)
superfamily, is known to have a pivotal role in the fibrinolytic
system. During fibrinolysis, tissue-type plasminogen acti-
vator (tPA) converts the proenzyme plasminogen into active
plasmin, a broad-spectrum proteolytic enzyme that de-
grades the fibrin clot. By binding to its active site, PAI-1
neutralizes tPA activity and thereby regulates the production
of plasmin (Huber, 2001). In addition to this critical role in
the fibrinolytic system, there is evidence supporting the
involvement of PAI-1 in several other biological phenomena,
including wound healing (Romer et al, 1991; Jensen and
Lavker, 1996; Irigoyen et al, 1999; Providence et al, 2000).
Interestingly, it has been reported that PAI-1 level is
significantly elevated under conditions associated with
tissue fibrosis and excessive fibrin accumulation, such as
sclerosis and keloid formation, supporting its role as an
important regulator of proteolytic environment in tissue
remodeling (Tuan et al, 1996; Higgins et al, 1999; Tuan et al,
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2003). The function of PAI-1 in wound repair is thought to be
tightly regulated in a spatiotemporal manner. Temporal
changes in the expression and/or the localization of PAI-1
are particularly likely to affect the stability of cell-to-ECM
adhesive complexes; increased synthesis or availability of
PAI-1 may inhibit cell detachment from substrates, con-
tributing to the stabilization of cell-to-matrix contact sites
(Ciambrone and McKeown-Longo, 1990; Germer et al,
1998). The involvement of PAI-1 in SPC-stimulated wound
healing raises the possibility that PAI-1 plays such a role
during this process. Although independently, both SPC and
PAI-1 have been clearly implicated in wound healing; the
relationship between these two molecules has not been
characterized. At present, limited data are available to
support the hypothesis that plasminogen activator systems
are involved in an SPC-stimulated wound-healing process.
For instance, SPC upregulates the cell-surface plasminogen
activity, and at the same time increases the cell surface
expression of both urokinase-type plasminogen activator
(uPA) and its receptor in keratinocytes (Wakita et al, 1998).
In this study, we demonstrate for the first time that SPC
induces the expression of PAI-1 in cultured human dermal
fibroblast, and that a G protein-coupled signaling cascade
is coordinately involved in this process.
Results
PAI-1 induction by SPC in healing wounds The healing
effects of several sphingolipid metabolites and related
derivatives (S1P, SPC, LPA, N-acetylphytosphingosine
(NAPS) and tetraacetylphytosphingosine (TAPS)) were
tested using a well-established rabbit ear wound model.
Of these, SPC demonstrated the most powerful promotion
of wound healing. Control wounds healed slowly, showing
incomplete closure of wounded areas at 4 d after injury,
whereas almost all SPC-treated areas were closed (Fig 1A
and B). These results were consistent with those of previous
reports (Sun et al, 1996; Wakita et al, 1998). Immunohisto-
chemical examination showed that treatment with SPC
significantly increased granulation tissue, and induced PAI-
1 production in the dermis (Fig 1C).
Induction of PAI-1 expression by SPC in human dermal
ﬁbroblasts To investigate the effect on PAI-1 production,
SPC was added to the fibroblast cells in serum-free
cultures. As PAI-1 is a secretary protein, we first measured
PAI-1 in conditioned media using an ELISA technique. As
shown in Fig 2A, SPC significantly induced the release of
PAI-1 in cultured human dermal fibroblast cells in a time-
dependent manner. In addition, SPC also induced the
release of uPA, the regulation of which is closely related to
that of PAI-1 production (Irigoyen et al, 1999). The levels of
PAI-1 were, however, several-fold higher than those of uPA.
Consistent with this observation, western blot analysis
showed that SPC treatment resulted in high-level induction
of intracellular PAI-1 protein, reaching a maximum at 12 h
and declining slightly by 24 h (Fig 2B, upper panel). SPC-
induced PAI-1 expression was also confirmed by reverse
fibrin autography, which revealed that PAI-1 activity also
increased concomitantly (Fig 2B, lower panel ). As shown in
Fig 2C and D, SPC significantly increased release, cellular
content and enzyme activity of PAI-1 in a concentration-
dependent manner. Northern blot analysis revealed a time-
dependent increase in PAI-1 mRNA level in response to
SPC (Fig 3). These results clearly demonstrated that SPC
induces the PAI-1 expression, at both the transcriptional
and translational levels, in cultured human dermal fibro-
blasts.
Involvement of G protein-coupled calcium increase in
SPC-induced PAI-1 expression In other systems, SPC is
known to affect downstream molecular events through G
protein-coupled signaling pathway (Seufferlein and Rozen-
gurt, 1995; Zhu et al, 2001; Xu, 2002). These findings led us
to investigate whether the G protein-coupled signaling
events were also involved in SPC-induced PAI-1 expression
in cultured human dermal fibroblasts. After pre-incubation
with pertussis toxin (PTx), an inhibitor for Gi/o subfamily, a
marked inhibition of SPC-induced PAI-1 expression was
observed (Fig 4A). On the other hand, pre-treatment of
tyrphostin A47, a receptor tyrosine kinase inhibitor, had no
effect on PAI-1 induction by SPC (Fig 4B). As SPC is known
to affect the intracellular calcium level ([Ca2þ ]i) via a G
protein-dependent pathway (Okajima and Kondo, 1995;
Chin and Chueh, 1998), we measured [Ca2þ ]i by laser
scanning confocal microscopy. Treatment with SPC led to a
robust [Ca2þ ]i increase, peaking at 7 s then decreasing to
50% of the maximum level at 15 s (Fig 5A). As anticipated,
this response was significantly diminished by pre-incuba-
tion with PTx (Fig 5B), indicating that Ca2þ mobilization by
SPC was partly mediated through PTx-sensitive G proteins.
The rapid and transient nature of the Ca2þ increase
Figure1
PAI-1 induction by SPC in healing wounds. (A) The inner ears of
rabbit were wounded using a biopsy punch at size of about 6 mm.
Wounded areas were covered with a plastic film, then injected daily
with 5 mM SPC solution for 4 d. (B) Sections were prepared with
paraffin, and stained with Hematoxylin–Eosin (H&E stain). (C) Immuno-
histochemical staining (IHC stain) was carried out with monoclonal
anti-PAI-1 antibody. After washing in PBS, sections were incubated
sequentially with biotinylated rabbit anti-mouse IgG and with perox-
idase-conjugated avidin. Black arrows indicate the wound edges. Red
arrows represent the PAI-1 staining in the dermis.
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suggested release from intracellular Ca2þ stores, rather
than influx from extracellular sources. To test this assump-
tion, cells were pre-treated with thapsigargin (an intracel-
lular Ca2þ chelator) or EGTA (to chelate extracellular Ca2þ ).
As shown in Fig 6A, pre-treatment with thapsigargin, but not
with EGTA, completely inhibited SPC-induced PAI-1 ex-
pression. The calcium ionophore A23187 also induced PAI-
1, and SPC interacted synergistically to enhance PAI-1
induction over a longer period than was seen with A23187
alone (Fig 6B).
Effect of PKC activation on SPC-induced PAI-1 expres-
sion It has been well established that an increase in [Ca2þ ]i
led to the activation of protein kinase C (PKC) in many
systems (Desai et al, 1993; Bitar and Yamada, 1995;
Seufferlein and Rozengurt, 1995). Cells were treated with
phorbol-12-myristate-13-acetate (PMA) for 30 min (PKC
activation) or for 4 h (PKC depletion) prior to SPC treatment.
PKC activation alone induced the PAI-1 production, which
was not further enhanced by SPC addition (Fig 7A). Pre-
treatment with PMA for a longer period had no effect on
PAI-I expression. Pre-treatment with Ro 31-8220, a PKC
inhibitor, however, resulted in marked suppression of SPC-
induced PAI-1 expression, indicating the involvement of
PKC activation in the process (Fig 7B).
Involvement of MAPK pathway in SPC-induced PAI-1
expression Cells were pre-treated with PD98059, a spe-
cific MAPK kinase 1/2 inhibitor. As shown in Fig 8A,
PD98059 significantly suppressed PAI-1 induction by SPC.
SPC was also shown to induce the rapid phosphorylation of
p42/44 extracellular signal-regulated kinase (ERK) (Fig 8B).
Figure 2
SPC-induced PAI-1 expression in cultured human dermal fibroblasts. (A) Cells were treated with 5 mM SPC at the indicated time points.
Plasminogen activator inhibitor-1 (PAI-1) and urokinase-type plasminogen activator (uPA) in conditioned media were quantified using ELISA kits.
Values represent the means and SEM from three independent measurements (po0.01 vs control). (B) PAI-1 content of cellular extracts was
analyzed by western blotting (upper panel), and enzyme activity was determined by reverse fibrin autography (lower panel). Cells were treated with
5 mM SPC at the indicated time points, and extracted in lysis buffer. Proteins (100 mg per lane) were separated on 10% polyacrylamide gels. PAI-1
denotes the purified PAI-1 positive control, which was obtained commercially. All bands migrated to a location corresponding to a molecular mass of
50 kDa. (C) Concentration-dependence of the effect of SPC on PAI-1 expression. Cells were treated with SPC at the indicated concentrations and
cultured for 12 h. The released PAI-1 and uPA were measured as in (A). (D) Cells were treated with SPC at the indicated concentrations for 12 h.
PAI-1 content and enzyme activity were assayed as in (B).
Figure 3
Northern blot analysis of PAI-1 expression in cultured human
dermal fibroblasts. Cells were treated with 5 mM SPC at the indicated
time points, and total RNA was isolated. Aliquots of 10 mg of total RNA
were loaded in each lane, and the ethidium bromide-stained gel was
photographed as a loading control.
Figure4
Effects of pertussis toxin (PTx) and tyrphostin A47 (A47) on SPC-
induced PAI-1 expression. Cells were preincubated for 4 h with the G
protein inhibitor PTx (A), or the receptor tyrosine kinase inhibitor A47 (B)
at the indicated concentrations. After the addition of 5 mM SPC,
incubation was continued for a further 12 h. Cellular content of PAI-1
was assessed by western blot analysis. Each lane contained 100 mg of
protein extracts.
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These results demonstrated that an MAPK signaling path-
way is involved in SPC-induced PAI-1 expression.
Discussion
In this study, we demonstrated that SPC, which stimulates
wound healing, induces PAI-1 production in human dermal
fibroblasts. Although SPC is a well-known potent mitogen
for a number of target cells, the effect of SPC is unlikely to
be explained simply by its impact on cell proliferation.
Wound healing is a multistep process, in which distinct yet
interrelated phases overlap. These include the inflammatory
phase, the proliferative phase, and the regeneration phase
(Chan et al, 2001). There is accumulating evidence that
components of the fibrinolytic system are indispensable to
one or more of these phases. For instance, plasminogen-
deficient mice display delayed wound healing after skin
injury, which is related to impaired keratinocyte migration
(Bugge et al, 1996; Romer et al, 1996). It has also been
reported that downregulation of PAI-1 synthesis, in HaCaT
cells transfected with an inducible antisense vector, marked-
ly impairs both the rate and extent of wound closure (Li et al,
2000). Additional study has revealed that plasmin induces
the degradation of collagen, thereby regulating fibroblast-
mediated tissue remodeling during wound healing (Pins
et al, 2000). These results clearly indicate that the function of
the fibrinolytic system is fundamental to proper wound
healing. Our results strengthen the notion that PAI-1 is one
important downstream effector in SPC stimulation of the
wound-healing process.
The sphingolipid metabolite S1P has been shown to act
as an intracellular second messenger (Olivera and Spiegel,
1993; Mattie et al, 1994; Spiegel, 1999). Many investiga-
tions, however, have revealed effects of S1P that are
sensitive to PTx, suggesting the presence of cognate G
protein-coupled receptors (Goodemote et al, 1995; Wu
et al, 1995; Zhu et al, 2001). Indeed, S1P was demonstrated
to activate the heterotrimeric G protein-coupled orphan
receptor Edg-1, which was originally cloned as an en-
Figure 5
Measurements of intracellular Ca2þ level.
Cells were loaded with 4 mM Fluo-3, AM for 40
min, and then subjected to confocal laser
scanning microscopy. SPC (5 mM) was added
alone (A) or following pre-treatment with 100 ng
per mL pertussis toxin (PTx) (B). Results are
presented as relative fluorescence intensity (RFI).
Figure 6
Effects of Ca2þ on SPC-induced PAI-1 expression. (A) Fibroblasts
were pre-treated with the intracellular Ca2þ chelator thapsigargin
(Thap) at 30 nM or with the extracellular chelator EGTA (1 mM) for 30
min. SPC (5 mM) was then added and incubation was continued for 12
h. (B) The calcium ionophore A23187 (1 mM) was added to cultures, and
cellular extracts were prepared at the indicated time points (upper
panel). In cotreatment experiments, SPC (5 mM) was added 12 h before
the treatment of A23187 (1 mM) (lower panel). Western blot analyses
were performed with 100 mg of cellular protein per lane.
Figure7
Effects of protein kinase C (PKC) activation on SPC-induced PAI-1
expression. (A) Fibroblasts were pre-treated with 100 nM phorbol-12-
myristate-13-acetate (PMA) for 0.5 or 4 h, followed by the addition of
5 mM SPC. Cells were further incubated for 12 h, and extracts were
subjected to western blotting for PAI-1. (B) Cells were pre-treated with
the PKC inhibitor Ro 31-8220 (Ro) at the indicated concentrations for
30 min, followed by SPC treatment as described above. Each lane
contained 100 mg of protein.
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dothelial differentiation gene (Lee et al, 1998). Several
groups have identified other members of a closely related
family of G protein-coupled orphan receptors that are
functional receptors for sphingolipid metabolites (Masana et
al, 1995; Yamaguchi et al, 1996; Ancellin and Hla, 1999;
Gonda et al, 1999). Thus, it is now believed that sphingolipid
metabolites exert their actions from the extracellular
environment via G protein-coupled receptors. Recently,
the specific high-affinity receptors for SPC, OGR1, and
GPR4, have been identified (Xu et al, 2000; Zhu et al, 2001).
OGR1 and GPR4 are highly homologous, and have similar
high affinities for SPC. It has been suggested, however, that
they act through different G protein pathways. SPC induced
the ERK activation in a PTx-insensitive manner in OGR1-
transfected cells, whereas the activation of ERK was
sensitive to PTx in GPR4-transfected cells. Our results
suggest that GPR4 may medicate SPC-induced PAI-1
expression in cultured dermal fibroblasts. The presence
and involvement of this type of receptor, however, remain to
be demonstrated.
Evidences in other systems have indicated that SPC
induces increases in [Ca2þ ]i, thereby affecting cell pro-
liferation (Seufferlein and Rozengurt, 1995; Chin and Chueh,
1998). We hypothesized that an increase in [Ca2þ ]i was also
involved in SPC-induced PAI-1 expression. As expected,
our confocal laser scanning microscopy data clearly
showed that SPC induced a rapid and transient increase
in [Ca2þ ]i. The involvement of [Ca
2þ ]i was further supported
by experiments showing both PAI-1 induction by calcium
ionophore and complete suppression of PAI-1 induction
following intracellular Ca2þ depletion by thapsigargin.
Interestingly, pre-treatment with PTx could not completely
suppress either the increase in [Ca2þ ]i or the induction of
PAI-1 expression. These results raise the possibility that
another pathway, together with PTx-sensitive G protein,
may be involved in SPC effect. One candidate is Rho
signaling pathway. In a preliminary study, PTx and C3-
exoenzyme (a specific inhibitor of Rho) each independently
caused partial inhibition of the induction of PAI-1 by SPC.
Marked synergistic enhancement of suppression was seen
when they were used together (data not shown). We are
currently investigating the possible involvement of the Rho
signaling pathway in SPC-induced PAI-1 expression.
Increased intracellular Ca2þ levels can activate numer-
ous downstream signaling targets, including PKC and
MAPK pathway. For example, SPC-induced MAPK activa-
tion was shown to be critically dependent on increases in
[Ca2þ ]i in porcine aortic smooth muscle cells, and PKC
activation was also shown to be involved in this process
(Chin and Chueh, 1998). In this study, we demonstrated that
the activations of PKC and MAPK pathway were involved in
SPC-induced PAI-1 expression. Together with previous
reports, our results raise the possibility that the activation
of PKC and MAPK pathway may be functional downstream
signaling events following SPC-induced increases in
[Ca2þ ]i. The putative relationship between these signaling
cascades, however, must be investigated further.
In summary, we have demonstrated that SPC promotes
both wound healing and PAI-1 production, and that a G
protein-coupled Ca2þ increase and additional downstream
signaling events are involved in this process.
Materials and Methods
Materials SPC was purchased from Matreya (Pleasant, California).
PAI-1 and uPA ELISA kits, monoclonal PAI-1 antibody, and purified
PAI-1 were obtained from American Diagnostica (Greenwich,
Connecticut). Pertussis toxin, tyrphostin A47, thapsigargin, EGTA,
A23187, PMA, Ro 31-8220, and PD 98059 were obtained from
Calbiochem (La Jolla, California). FBS, penicillin/streptomycin
solution, trypsin/EDTA, and DMEM were from Gibco BRL (Rock-
ville, Maryland), and plasminogen and thrombin were from Sigma
(St Louis, Missouri). Anti-phospho-p42/44 ERK antibody was
purchased from New England BioLabs (Beverly, Massachusetts).
Fluo-3, AM was supplied by Molecular Probes (Eugene, Oregon).
In vivo testing Five Netherlands rabbits, between 10 and 12 wk of
age, were anesthetized with phenobarbital. All tests were approved
by IRB (Institute of Medical Research, College of Medicine,
Chungnam National University). Full-thickness wounds, approxi-
mately 6 mm in diameter that did not cross the muscle fascia were
made in the inner surface of the ear using a biopsy punch. The
wounds were not sutured, but were dressed with a transparent
plastic film. Experimental groups received daily injections of 5 mM
SPC solution into the wounded areas, which were then re-covered
with plastic film. Rabbits were euthanized after 4 d of treatment,
and the wounded areas were dissected out and embedded in
paraffin. Sections were stained with hematoxylin and eosin to
examine cell migration and remodeling. Immunohistochemical
staining was performed as follows. After brief washing in PBS,
sections were blocked in PBS containing 0.5% skim milk, and
incubated for 2 h at room temperature with a 1:200 dilution (5 mg
per mL) of monoclonal anti-PAI-1 antibody. After further washing in
PBS, sections were incubated sequentially with biotinylated rabbit
anti-mouse IgG and with peroxidase-conjugated avidin.
Cell culture Normal human skin samples were obtained from
circumcisions, in accordance with the ethical committee approval
process of Chungnam National University Hospital. Specimens
were briefly sterilized in 70% ethanol, minced, and then incubated
in DMEM supplemented with 10% FBS and antibiotics. Dermal
fibroblasts normally outgrew from the explants after 5–7 d. At
confluence, cells were routinely passaged using a 1:4 split ratio.
Cells were used between passages 4 and 16. For treatment with
SPC, approximately 1  106 cells were seeded on 100 mm culture
Figure 8
Involvement of a mitogen-activated protein kinase (MAPK) path-
way in SPC-induced PAI-1 expression. (A) Cells were incubated with
the specific MAPK kinase 1/2 inhibitor PD98059 at the indicated
concentrations for 30 min, and then stimulated with 5 mM SPC for 12 h.
Cellular PAI-1 was assayed by western blot analysis. (B) Cells were
treated with 5 mM SPC at the indicated time points. Cellular extracts
were separated on 8% polyacrylamide gels and subjected to western
blot analyses for phospho-p42/44 ERK (p-ERK) or p42/44 ERK (total-
ERK).
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dishes and grown to confluence. Cells were starved of serum for
24 h, then treated with SPC in serum-free medium.
PAI-1 and uPA ELISAs Levels of PAI-1 and uPA in conditioned
media were quantified using ELISA kits according to the
manufacturer’s recommended protocols. Measurements were
repeated at least three times, with independent cell batches
obtained from three different donors.
PAI-1 Western blotting Cell extracts were prepared in lysis buffer
containing 62.5 mM Tris, pH 6.8, 50 mM DTT, 2% SDS, 10%
glycerol, and proteinase inhibitors. Total protein was measured
using a Bradford protein assay kit (Bio-Rad Laboratories, Hercules,
California). Samples were run on 10% SDS-polyacrylamide gels,
transferred onto nitrocellulose membranes, and incubated with
anti-PAI-1 antibody (1:200 dilution in 2.5% skim milk in PBS-T) for
either 2 h at room temperature or overnight at 41C with gentle
agitation. Blots were then incubated with peroxidase-conjugated
anti-mouse IgG (Amersham, Buckinghamshire, UK) at a dilution of
1:2000 in 2.5% skim milk in PBS-T, and were developed by
enhanced chemiluminescence (Amersham).
Reverse ﬁbrin autography The PAI-1 activity in cell lysates was
assayed according to a slight modification of the method reported
previously (Nordt et al, 1995). Samples of cell extracts (100 mg)
were run on 10% SDS-polyacrylamide gels, under non-reducing
conditions. Following electrophoresis, SDS was removed by
washing with 2.5% Triton X-100 for 90 min at room temperature.
Gels were placed on an agarose indicator containing thrombin
(0.06 U per mL), purified plasminogen (5 mg per mL), fibrinogen (2
mg per mL), and tPA (0.05 U per mL). Gels were incubated
overnight at 41C to allow penetration of proteins into the fibrin-
agarose, and then incubated for 3–4 h at 371C to induce enzyme
activity. PAI-1 activity was visualized by the appearance of an
opaque band.
Northern blot analysis Total RNA samples (10 mg) were electro-
phoresed on 1% agarose gels containing formaldehyde and
transferred onto Hybond-Nþ membranes (Amersham). Blots were
prehybridized for 30 min at 621C, then hybridized overnight at 621C
in the same solution containing 32P-labeled probe. Following
hybridization, blots were washed, and then analyzed using a Fuji
BAS 2500 phosphoimager (Fuji Film, Tokyo, Japan).
Measurement of [Ca2þ ]i Cells were grown on coverslips for 24 h,
under serum-free conditions, then incubated with 4 mM Fluo-3, AM
for 40 min. After three washes with serum-free medium, coverslips
were mounted in perfusion chambers of our own design and
subjected to confocal laser scanning microscopy (Zeiss LSM 410;
Carl Zeiss, MicroImaging, Thornwood, New York). Scanning was
performed at 1 s intervals with 488 nm excitation argon laser and
515 nm long-pass emission filter. SPC was added to the cells using
an automatic pump system. All images were processed to analyze
the changes in Ca2þ concentration at the cellular level. Results are
expressed as relative fluorescence intensity.
Statistical analysis Data for PAI-1 and uPA ELISAs were
statistically evaluated using Student’s t test. Statistical significance
was set at po0.01.
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